StockIQ.techTwist Bioscience Corporation (TWST) Stock Analysis
Free AI-powered analysis and research for Twist Bioscience Corporation stock
Sector: Healthcare
TWST snapshot
Data as of 9 Oct 2026 close. Updated daily.
Twist Bioscience Corporation scores 28/100 on StockIQ's model, which reads as negative signals overall. The price is above its 200-day average and at 69% of its 52-week range, up 412.3% over the past year. Latest reported figures show a profit margin of -31.7%, return on equity of -29.6% and revenue growth of +23.2%.
What is driving the score
- RSI Neutral: +5
- Below 20-day MA: -6
- MACD Bearish: -8
- Strong Revenue Growth (23.2%): +8
- Unprofitable (-31.7%): -15
- Low Debt (0.24 D/E): +8
- Strong Liquidity (2.67 Current Ratio): +8
- Negative ROE (-29.6%): -10
- High P/B (21.38): -5
- Strong Long-term Uptrend: +8
- Extreme Overextension (+412.3% over 1 year): -15
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full TWST report
Twist Bioscience Corporation (TWST) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze TWST Now →📰 Latest Update
Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera
Mon, October 12, 2026 at 2:00 PM UTC 3 min read
The Global Synthetic Antibody Library Market is projected to grow at a 12% CAGR from 2026 to 2030, driven by advancements in AI design and increasing demand for synthetic antibodies. Key players such as Charles River, Twist Bioscience, GenScript, and AbCellera are positioned to capitalize on this growth. For investors, this trend highlights significant opportunities in the biotech sector, particularly in companies leveraging innovative technologies to enhance antibody development.